A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01131104|
Recruitment Status : Completed
First Posted : May 26, 2010
Results First Posted : April 5, 2018
Last Update Posted : April 5, 2018
|Condition or disease||Intervention/treatment|
|Nonarteritic Anterior Ischemic Optic Neuropathy||Drug: PDE5 Inhibitors|
|Study Type :||Observational|
|Actual Enrollment :||345 participants|
|Official Title:||A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
Participants with NAION who have used PDE5 inhibitors
Drug: PDE5 Inhibitors
Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
- 30-Day Person Time Analysis Risk of NAION Associated With PDE5 Inhibitor Use [ Time Frame: 30 days prior to NAION onset ]Total participant days of PDE5 inhibitor exposure within 30 days prior to onset of NAION.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131104
Show 44 Study Locations
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fr- 9 AM-5 PM Eastern time (UTC?GMT - 5 hours, EST)||Eli Lilly and Company|